A detailed history of Smith, Moore & Co. transactions in Amgen Inc stock. As of the latest transaction made, Smith, Moore & Co. holds 7,583 shares of AMGN stock, worth $2.23 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
7,583
Previous 6,996 8.39%
Holding current value
$2.23 Million
Previous $2.19 Million 11.81%
% of portfolio
0.24%
Previous 0.23%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$309.38 - $337.38 $181,606 - $198,042
587 Added 8.39%
7,583 $2.44 Million
Q2 2024

Aug 14, 2024

BUY
$262.75 - $319.31 $534,696 - $649,795
2,035 Added 41.02%
6,996 $2.19 Million
Q1 2024

May 10, 2024

BUY
$268.87 - $324.56 $29,306 - $35,377
109 Added 2.25%
4,961 $1.41 Million
Q4 2023

Feb 13, 2024

SELL
$255.7 - $288.46 $10,228 - $11,538
-40 Reduced 0.82%
4,852 $1.4 Million
Q3 2023

Nov 14, 2023

SELL
$218.65 - $271.46 $115,884 - $143,873
-530 Reduced 9.77%
4,892 $1.31 Million
Q2 2023

Aug 11, 2023

BUY
$214.27 - $253.37 $50,996 - $60,302
238 Added 4.59%
5,422 $1.2 Million
Q1 2023

May 12, 2023

SELL
$225.79 - $275.2 $14,676 - $17,888
-65 Reduced 1.24%
5,184 $1.25 Million
Q4 2022

Feb 13, 2023

SELL
$229.03 - $291.01 $195,591 - $248,522
-854 Reduced 13.99%
5,249 $1.38 Million
Q3 2022

Nov 14, 2022

SELL
$224.46 - $253.15 $49,830 - $56,199
-222 Reduced 3.51%
6,103 $1.38 Million
Q2 2022

Aug 12, 2022

BUY
$230.71 - $256.74 $23,071 - $25,674
100 Added 1.61%
6,325 $1.54 Million
Q1 2022

May 12, 2022

SELL
$219.27 - $242.57 $19,515 - $21,588
-89 Reduced 1.41%
6,225 $1.51 Million
Q4 2021

Feb 08, 2022

BUY
$198.88 - $227.6 $82,137 - $93,998
413 Added 7.0%
6,314 $1.42 Million
Q3 2021

Nov 12, 2021

BUY
$212.27 - $248.7 $27,595 - $32,331
130 Added 2.25%
5,901 $1.26 Million
Q2 2021

Aug 10, 2021

BUY
$233.58 - $259.14 $21,022 - $23,322
90 Added 1.58%
5,771 $1.41 Million
Q1 2021

May 14, 2021

BUY
$221.91 - $258.6 $776,685 - $905,100
3,500 Added 160.48%
5,681 $1.41 Million
Q4 2020

Feb 16, 2021

BUY
$216.38 - $257.67 $15,362 - $18,294
71 Added 3.36%
2,181 $501,000
Q3 2020

Nov 12, 2020

SELL
$234.65 - $260.95 $109,816 - $122,124
-468 Reduced 18.15%
2,110 $536,000
Q2 2020

Aug 10, 2020

BUY
$197.81 - $242.74 $41,342 - $50,732
209 Added 8.82%
2,578 $608,000
Q1 2020

May 15, 2020

SELL
$182.24 - $241.7 $5,831 - $7,734
-32 Reduced 1.33%
2,369 $480,000
Q4 2019

Feb 07, 2020

SELL
$189.21 - $243.2 $9,649 - $12,403
-51 Reduced 2.08%
2,401 $579,000
Q3 2019

Nov 07, 2019

BUY
$174.11 - $208.62 $98,023 - $117,453
563 Added 29.8%
2,452 $474,000
Q2 2019

Aug 15, 2019

BUY
$166.7 - $195.41 $85,517 - $100,245
513 Added 37.28%
1,889 $348,000
Q1 2019

May 07, 2019

SELL
$180.87 - $203.88 $90,254 - $101,736
-499 Reduced 26.61%
1,376 $261,000
Q4 2018

Feb 15, 2019

BUY
$178.4 - $208.25 $79,744 - $93,087
447 Added 31.3%
1,875 $365,000
Q3 2018

Nov 15, 2018

BUY
$185.29 - $208.89 $9,820 - $11,071
53 Added 3.85%
1,428 $296,000
Q2 2018

Aug 14, 2018

BUY
$166.05 - $186.51 $228,318 - $256,451
1,375 New
1,375 $254,000
Q1 2018

May 14, 2018

SELL
$169.43 - $198.0 $397,482 - $464,508
-2,346 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$168.79 - $188.59 $337 - $377
2 Added 0.09%
2,346 $408,000
Q3 2017

Nov 02, 2017

BUY
$167.29 - $191.0 $392,127 - $447,704
2,344
2,344 $437,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Smith, Moore & Co. Portfolio

Follow Smith, Moore & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.